Celldex Therapeutics reported $47K in Ordinary Share Capital for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ordinary Share Capital Change
Agenus AGEN:US USD 2.95M 120K
Amgen AMGN:US USD 32.37B 1.03B
Applied Genetic Technologies AGTC:US USD 68K 17K
Aptinyx Inc APTX:US USD 677K 0
Bristol Myers Squibb BMY:US USD 292M 0
Celldex Therapeutics CLDX:US USD 47K 0
Cytrx CYTR:US USD 43.48K 4.7K
Glaxosmithkline GSK:US GBP 1.5B 136.72M
Immunogen IMGN:US USD 2.21M 2K
Nektar Therapeutics NKTR:US USD 19K 0
Newlink Genetics NLNK:US USD 83K 0
Northwest Biotherapeutics NWBO:US USD 1.05M 17K
Rigel Pharmaceuticals RIGL:US USD 173K 0
Roche Holding ROG:VX 107M 53M
Seattle Genetics SGEN:US USD 185K 1000